Prerpints.org logo
Preprint
Review

Basic-Clinical Analysis of Parathyroid Cancer

Altmetrics

Downloads

146

Views

67

Comments

0

Submitted:

05 August 2024

Posted:

06 August 2024

You are already at the latest version

Alerts
Abstract
Parathyroid cancer (PC) presents clinically as a case of hyperparathyroidism associated with local compression symptoms. The definitive diagnosis of PC is complex as it requires unequivocal criteria of invasion in postoperative biopsy. Given the difficulty in confirming the diagnosis of PC, attempts have been made to address this problem through the search for biomarkers, mainly using immunohistochemistry. Within this theme, the phenomenon of epithelial-mesenchymal transition and cancer stem cells markers have been scarcely studied; and could eventually help discriminate between a diagnosis of parathyroid adenoma or carcinoma. This review presents a clinical approach to the disease; as well as providing a state of the art analysis of basic biomarkers in diagnosis and future projections in this field.
Keywords: 
Subject: Biology and Life Sciences  -   Other

1. Clinical Approach

1. Primary Hyperparathyroidism

Primary hyperparathyroidism (PHPT) is a common endocrine disorder characterized by excessive and autonomous secretion of parathyroid hormone (PTH) by one or more parathyroid (PT) glands, resulting in asymptomatic or symptomatic hypercalcemia [1].
Regarding the etiology of PHPT, a spectrum of proliferative disorders in the PT gland is described: solitary parathyroid adenoma (80%), multiglandular parathyroid disease (previously known as parathyroid hyperplasia, 10-15%), multiple parathyroid adenomas (5%), and parathyroid carcinoma (~1%) [2,3].
Epidemiologically speaking, PHPT is traditionally a disease diagnosed in postmenopausal women, with a predominance in African American and Caucasian populations. Its prevalence and incidence depends mainly on the availability of PTH and serum calcium measurement, associated with screening protocols, which has favored the transition to early and asymptomatic diagnosis [4]. American studies estimate an age-adjusted prevalence of 233 and 85 per 100,000 inhabitants for female and male populations, respectively; showing a 2.5:1 female predominance and a tripling of prevalence over a 15-year period (1995-2020). In addition, with advancing age (>45 years), a pronounced increase in sex-specific incidence differences is described, with a significant female predominance [5].
Clinically, most patients are asymptomatic or present with nonspecific symptoms such as fatigue, depression, or mild cognitive impairment [6]. Persistence of the disease favors symptomatology secondary to hypercalcemia, characterized by renal involvement (nephrolithiasis and renal insufficiency), gastrointestinal disease (peptic ulcer and pancreatitis), musculoskeletal disorders (fractures on pathological bone, fibrous osteitis cystica, osteoporosis, chondrocalcinosis, and arthritis), neuropsychiatric symptoms (lethargy, confusion, psychosis, and coma), among other symptoms such as polydipsia, polyuria, abdominal pain, nausea, and vomiting [6,7]. Simultaneous hypercalcemia and elevated PTH levels (or inappropriately normal levels) represents the most important factors to diagnosticate PHPT [2]. The diagnosis of PHPT requires biochemical analysis revealing.
Surgical treatment (parathyroidectomy) is the only definitive treatment for PHPT, and it is indicated in symptomatic patients or asymptomatic patient who meets the criteria determined by the Fifth International Workshop (<50 years, serum calcium >1.0 mg/dl above the upper normal level, bone mineral density showing T Score <2.5 in those over 50 years, fracture on pathological bone, nephrolithiasis, nephrocalcinosis estimated glomerular filtration rate (eGFR) <60 ml/min, or hypercalciuria) [8,9]. Classically, surgical management of PHPT involves bilateral cervical exploration; however, advances such as intraoperative PTH measurement and improved preoperative localization methods have favored the implementation of minimally invasive techniques, remote approaches (retroauricular, axillary, submammary, transoral) and robotic-assisted surgery. Thus, parathyroidectomy is an active area of research, where various modern techniques claim better aesthetic outcomes, surgical times, or postoperative recovery [7].

2. Parathyroid Cancer

As previously mentioned, parathyroid carcinoma (PC) is the least common etiology in the context of PHPT (about 1%). It is an uncommon endocrine neoplasm, currently accounting for 0.005% of malignant neoplasms in western population [10]. The estimated annual incidence of this condition is 3.5-5.7 cases per 10,000,000 individuals, with a peak incidence in the fifth decade and no gender differences. A recent retrospective study of the SEER database analyzed 609 cases of PC, determining a higher incidence in males (52.2%), predominance in Caucasian population (75.4%), average age at diagnosis of 62 years, mainly adenocarcinoma histology (99.7%), with 36.8% of cases being organ-confined at the time of diagnosis. Risk factors for mortality include older age (>40 years), tumor size >4 cm, male gender, metastasis, and poor histological differentiation [11].
The etiology of PC is unknown, but an increased incidence has been associated with cervical irradiation and stage V chronic kidney disease [12]. This cancer typically presents as spontaneous disease; however, it can also be associated with specific syndromes such as hyperparathyroidism-jaw tumor syndrome (HPT-JT) or multiple endocrine neoplasia (MEN) types 1 and 2A. Genetically, a relationship has been established between mutations in the CDC73 gene (which codes for parafibromin) and spontaneous PC (present in up to 70% of cases) and familial forms [10,12]. Parafibromin is a tumor suppressor protein that can be detected by immunohistochemistry, and its decrease is associated with increased cell proliferation, apoptosis, and chromosomal instability [13].
PC presents clinically as a case of hyperparathyroidism (described earlier) which precedes local compression symptoms. Additionally, PC tends to have higher hormonal activity than PT adenomas and hyperplasias, resulting in serum PTH levels up to 10 times the normal value and hypercalcemic crisis in up to 12% of patients (serum calcium >14 mg/dL, oligoanuria, and neuropsychiatric symptoms). Among the symptoms associated with PHPT, renal (nephrolithiasis and renal insufficiency) and skeletal (bone pain, fractures in pathological bone, osteoporosis, etc.) manifestations are most common. On physical examination, a palpable cervical mass can be found in 40-70% of cases, which may be associated with compressive symptoms of the upper airway and digestive tract. It is described that up to 10% of these carcinomas are non-functioning, and in consequence are diagnosed later, usually due to compressive symptoms. Cervical lymph nodes are the main site of metastasis, present in 15-20% of cases; followed by distant metastasis to lung, liver, and bone (1%) [14,15].
Clinical suspicion of PC is important due to the similarity with other proliferative pathologies within the PHPT spectrum, and the rarity of this carcinoma. In this context, it is important to remember the preoperative suspicion criteria: male gender, young age (<50 years), concomitant renal and skeletal manifestations, palpable cervical mass, paralysis of the laryngeal nerves, plasma PTH levels >10 times the normal level, serum calcium >14 mg/dL or hypercalcemic crisis, local invasion of adjacent structures and suspicion of metastasis on imaging studies [10,14].
Despite the previously described criteria, the definitive diagnosis of PC is complex as it requires unequivocal criteria of invasion in postoperative biopsy; including: angioinvasion, lymphoinvasion, perineural invasion, invasion of neighboring soft tissues and musculoskeletal structures, thyroid, esophagus, etc., and/or presence of lymph node or distant metastasis. The aforementioned are absolute criteria, and meeting just one of them is sufficient for diagnosing PC. The cytological or histological characteristics of the tumor are not sufficient to make the diagnosis. This determines the difficulty in discriminating between PT adenoma and carcinoma. Consequently, malignancy-associated criteria have been established. The presence of these criteria indicates a high risk of malignant behavior, acquiring the name of “atypical parathyroid tumor” (however, not sufficient for PC diagnosis). These criteria include trabecular or “sheet-like” architecture, wide bands of intraglandular fibrosis, diffuse cellular atypia, enlarged nucleoli, >5 mitoses per 10 mm3, atypical mitoses, coagulation necrosis, capsular involvement without extension into the periglandular fibroadipose tissue [3,16].
Given the difficulty in confirming the diagnosis of PC, attempts have been made to address this problem through the search for biomarkers using immunohistochemistry (IHC); however, none have proven to be pathognomonic of this disease (see state of the art analysis) [16].
Within this theme, the phenomenon of epithelial-mesenchymal transition (EMT) and cancer stem cells (CSC) markers have been scarcely studied; and could eventually help discriminate between a diagnosis of parathyroid adenoma or carcinoma.
Regarding treatment, surgical management is the only curative option, prior medical management of metabolic abnormalities. This consists of an en bloc resection of the primary tumor, along with the ipsilateral thyroid lobe and isthmus, as well as involved pre-thyroid muscles and central neck lymph node dissection [10,14].
On the other hand, PC is considered radioresistant; however, some series report lower disease progression and possibly lower recurrence when used as postoperative adjuvant treatment [12]. Despite this, the use of adjuvant radiotherapy has not shown benefits in overall survival. Additionally, a better 5-year survival is described in patients treated surgically compared to isolated radiotherapy [11]. Currently, its adjuvant use is reserved for patients at high risk of locoregional recurrence [17,18].
Similarly, the use of chemotherapy in PC has historically shown low to no efficacy. A recent report describes a favorable response with the use of the multikinase inhibitor Sorafenib in a case of PC with lung metastases, although further evaluation is needed [10,19].
Reports by Christakis et al. highlight that there have been no significant changes in the management and prognosis in overall survival in the past 35 years at the University of Texas MD Anderson Cancer Center, underscoring the importance of promoting research and progress in treatments for this cancer [17].
Long-term survival is favorable, with 5- and 10-year survival rates ranging from 85-91% and 49-87.6%, respectively. In general, mortality is secondary to complications associated with hypercalcemia, rather than tumor burden [12].

2. State of the Art Analysis in Parathyroid Cancer

1. Parathyroid Cancer: Diagnosis and Utility of Frequent Biomarkers

As previously mentioned, the definitive diagnosis of PC requires unequivocal criteria for invasion in the postoperative biopsy (angioinvasion, lymphoinvasion, perineural invasion, invasion of neighboring soft tissues and musculoskeletal structures, thyroid, esophagus, etc. and/or presence of lymph node or distant metastasis). The mentioned criteria are known as absolute criteria, and meeting just one is sufficient for the diagnosis of PC. On the other hand, the cytological or histological characteristics of the tumor are not sufficient to make the diagnosis, which determines the difficulty in discriminating between PT adenoma and carcinoma. Criteria associated with malignancy can be reviewed in the Introduction section [3,16]. Given the difficulty in confirming the diagnosis of PC, attempts have been made to address this problem by searching for biomarkers mainly through IHC; however, none have been found to be pathognomonic of the disease [16].
In conclusion, due to the low frequency of this cancer, most biomarker studies in PC are in early phases, do not have clear definitions regarding results, show variations in populations used and reporting methods, and also have a small sample size (1-57 cases per study), which has made it difficult to perform statistical analyses. In this context, a recent systematic review of potential biomarkers in PC by Davies et al. significantly identified (in at least one study) 5 markers in serum and 13 in tissue. Specifically, the markers that showed the strongest evidence in serum are calcium and PTH (15 and 16 studies, respectively), with a cutoff of 3 mmol/L (12.02 mg/dL) and >3 times the upper limit of normal (ULN) for calcium and PTH, respectively, in order to suspect PC. In addition, the presence of elevated alkaline phosphatase or creatinine, as well as decreased 25-hydroxyvitamin D, are independently associated with suspicion of PC. It is likely that these latter markers are associated with a biochemical manifestation of disease severity rather than directly related to the pathophysiology of the disease (as is the case with serum calcium and PTH) [20].
On the other hand, multiple biomarkers have been described in tissue, which implies access to tissue and post-surgical analysis by the pathologist. Despite the existence of several markers, none of them are pathognomonic of PC and it is currently an active area of research, where every study is an advancement.
Parafibromin is the main biomarker studied in tissues; it is a tumor suppressor protein, encoded by the Cell Division Cycle 73 (CDC73, previously HRPT2) gene. Its function lies in the repression of cyclin D1, consequently stopping the cell cycle, and it is also associated with the regulation of the P53 pathway. Mutations in this gene are associated with decreased function and detection by IHC [16]. As a result, the absence of parafibromin is associated with diagnostic evidence and worse prognosis in PC. Over 19 scientific articles have described its association with PC, showing significant results in 7 of them [20]. Despite the above, there is an overlap in the presence of this gene and protein between PC and adenomas, as CDC73 mutations have been described in 1-6% of adenomas. Given the low frequency of this cancer, a nearly perfect specificity is required for its use as a screening tool in PT tumors (as a standalone marker), which complicates its use in this aspect. However, it is a strong tool for ruling out malignancy in case of positive immunoreactivity. It should be used while considering the clinical context of the patient, and currently it is associated with other markers [21].
Galectin 3 is a glycoprotein involved in pathophysiological processes such as fibrosis, inflammation, and cancer. It plays a regulatory role in the tumor microenvironment, specifically by suppressing T cells through inhibition of T-cell receptor (TCR)-mediated signaling. Its overexpression has been associated with tumor growth and invasion [22]. Six scientific articles have associated the overexpression of Galectin 3 with PC, but there are reports that raise doubts about the utility of this marker [20]. Recently, Mohammed et al. reported only 15% positivity in PC, showing a poor profile as a biomarker: sensitivity (Sen) 6%, specificity (Spe) 29%, positive predictive value (PPV) 19%, and negative predictive value (NPV) 10% [23]. Further studies are needed for this biomarker.
Ki67 is a nuclear protein expressed in proliferating cells (active phase of the cell cycle) and downregulated during the G0 phase. Therefore, increased staining for this antigen suggests a higher proportion of proliferative cells in the histological sample. It is a diagnostic and prognostic tool used in multiple types of carcinomas (especially colorectal), where staining >5% may aid in the diagnosis of PC, although it does not yet qualify as a diagnostic criterion (thus, it is used in association with other markers). However, there are reports that do not show significant differences between adenomas and PC, indicating the need for further studies [16,20,24].
PGP9.5 (protein gene product 9.5) is the protein product of UCHL1 (ubiquitin carboxyl-terminal esterase L1) and is mainly expressed in nervous and neuroendocrine tissues. Its presence has been associated with aggressive neoplasms (colorectal, prostate, gastric, and pulmonary). There are at least two studies where PGP9.5 is reported to be overexpressed in PC, but further studies are needed to validate these findings [20,25].
APC (Adenomatous polyposis coli) is a tumor suppressor gene that acts by inhibiting the Wnt signaling pathway. It can be evaluated through polymerase chain reaction (PCR) or its protein product via IHC, and its loss of expression has been associated with carcinogenesis. Currently, it is also linked to other carcinomas such as colon and liver cancer. At least two studies have shown a significant association with PC, but, similar to other markers, there are articles that have not demonstrated this association, emphasizing the need for further studies on this topic [20].
The protein p27 acts as a tumor suppressor and a cyclin-dependent kinase inhibitor, which slows down the cell cycle. Loss of p27 expression is suggestive of PC, with at least one statistically relevant study supporting this association [16,20].
The decreased expression of the calcium-sensing receptor (CaSR) has been reported in PC, which is a rare phenomenon in benign PT tumors. However, the reports on this association are inconsistent, which makes it challenging to use CaSR as a reliable biomarker. Filamin A is a scaffold protein that binds to the CaSR and facilitates the activation of the MAPK pathway. In a study by Storvall et al., cytoplasmic expression of Filamin A was significantly higher in PC compared to adenomas, suggesting its potential as a biomarker for PC [16,26].
Table 1. Main markers studied in PC.
Table 1. Main markers studied in PC.
Marker Source Characteristics References
Calcium Serum Increased [27,28]
PTH Serum Increased [27,28,29,30]
Alkaline phosthatase Serum Increased [27,28,31,32]
Vitamin D Serum Decreased [33]
Parafibromin Tissue Mutated/decreased [23,33,34,35,36,37]
Galectin 3 Tissue Increased [23,37,38,39,40]
Ki67 Tissue Increased [23,30,33,37,40]
PGP 9.5 Tissue Increased [37,41]
APC Tissue Decreased [23,42]
P27 Tissue Decreased [43,44]
CaSR Tissue Decreased [16,26]
Apart from the markers mentioned above, there are limited studies on other markers such as: AgNOR, CDC73, cyclin D1, P21, P53, Rb (retinoblastoma gene), BCL2, BAX, Mdm2, PTEN, among others. Most of these are individual studies and often lack statistical analysis. Undoubtedly, this is an area of research that is still not well developed but holds great promise for the future. It is important to note that no single biomarker has been able to differentiate PC from adenomas on its own; but rather these markers can serve as auxiliary tools in diagnosis and prognosis [3,20].

2. Epithelial-Mesenchymal Transition and Cancer Stem Cells in Parathyroid Carcinoma

The presence of CSC and patterns of dedifferentiation, such as EMT, have been established in various types of cancer. Specifically, EMT is a cellular process in which an epithelial cell acquires a mesenchymal phenotype and behavior due to the downregulation of specific epithelial markers (such as cytokeratin and E-cadherin) and upregulation of mesenchymal markers (such as fibronectin, N-cadherin, and vimentin). Consequently, these cells acquire a fibroblast-like morphology, lose apico-basal polarity, as well as, interaction with the basement membrane and therefore exhibit increased migratory capacity and invasive properties [45]. This process is regulated by complex molecular pathways, and can be described based on certain molecular markers. The transcription factors (EMT-TFs) involved in this process include Zeb1, Zeb2, Snail1, Snail2 (Slug), and Twist1, which are responsible for silencing genes expressed in epithelial cells and inducing those specific to mesenchymal cells [46].
At the post-translational level, increased expression of certain proteins such as N-cadherin, vimentin, fibronectin, matrix metalloproteinases (-2, -3, -9) and downregulation of E-cadherin, cytokeratin, occludins, desmoplakin, among others, are canonical events in this cellular process [47].
On the other hand, Cancer Stem Cells (CSCs) or tumor-initiating cells are cancer cells that share characteristics with stem or progenitor cells. Of particular note is their ability to differentiate into other cell lineages and undergo self-renewal through symmetric (generating two stem cells) or asymmetric (generating one stem cell and one differentiated cell) cell division. CSCs are involved in tumour formation, invasion, metastasis and even resistance to chemotherapy and radiotherapy.. There are multiple methods for detecting CSCs, with the characterization of CSCs using cellular biomarkers being a prominent approach. These biomarkers typically correspond to membrane antigens and transcription factors, and may vary depending on whether the tumors are solid or hematological cancers. In solid tumors, prominent surface markers include CD24, CD44, CD90, CD133, and EpCAM, while intracellular markers such as Sox2, Oct-3/4, and Nanog are also used, among others [48,49].
There are limited reports specifically aimed at evaluating these phenomena in PC. According to a recent review by Uljanovs et al., the low incidence of PC has hindered studies on epithelial-mesenchymal transition in this cancer [16].
Fendrich et al. compared the expression of EMT markers (E-cadherin, Snail, and Twist) using IHC in normal PT tissue (2 cases) and PT adenomas (25 cases), hyperplasia (25 cases), and PC (9 cases). In all cases of PC, loss of membranous staining of E-cadherin was observed, showing a characteristic cytoplasmic staining pattern indicative of EMT; while membranous staining was preserved in normal tissues and benign proliferative disorders. On the other hand, Snail and Twist lost the homogeneous expression pattern seen in the control groups, being limited to the invasive front in the cancerous tissue samples. These changes in marker expression observed in PC suggest an important role of EMT in the tumorigenesis of this cancer. Although further studies are needed, this could be a potential tool to distinguish between PT adenomas and carcinomas [50].
Schneider et al. further supported the previously described change in immunostaining pattern and compared the expression of E-cadherin in atypical PT adenomas (currently known as atypical parathyroid tumors), benign PT adenomas, and PC. It was concluded that atypical tumors showed membranous staining of E-cadherin, characteristic of benign proliferative disorders of PT tissue, in contrast to PC. The potential use of E-cadherin as a differentiating marker between these two clinical entities was suggested [51].
Meanwhile, Pandya et al. conducted a genomic profiling of 17 cases of PC using whole-exome sequencing. Among the results, recurrent somatic mutations were described in the Zeb1 gene (3 cases), a transcriptional repressor associated with tumor invasion and metastasis through the activation of EMT [52].
In addition to the previously mentioned biomarkers, the study of intermediate filaments has shown that cytokeratin 19 presents a progressive upregulation in proliferative PT lesions (adenoma, hyperplasia, and cancer), statistically significant but markedly heterogeneous. Further studies of this intermediate filament in PC are recommended. On the other hand, vimentin corresponds to a mesenchymal intermediate filament with important functions in cell mobility, signaling, and migration; however, it is difficult to study in PT tissue due to its glandular histology. Recently, Ulijanovs et al. described that the fraction of parenchymal cells positive for vimentin varies in healthy tissue, hyperplasia, adenoma, and carcinoma, with percentages of 9%, 11.7%, 19.3%, and 36.8% respectively. Regarding location, in healthy tissue, vimentin expression is only perinuclear, while carcinoma shows significant cytoplasmic expression, and adenomas and hyperplasias show a combination of both patterns [16,53].
On the other hand, CD44, a surface glycoprotein and a recognized CSC marker, has been less studied in PT pathology, and currently, is not believed to play a significant role in PT tumors given its absence in normal PT tissue and proliferative disorders. This is interesting considering that, generally, neuroendocrine tumors express this marker. This discrepancy could possibly be explained by the fact that PT tissue has an embryological origin in the neural crest, which is CD44(-), whereas neuroendocrine tumors that are CD44(+) originate from the endoderm. This could also explain the presence of E-cadherin, Snail, and Twist in normal and benign proliferative PT tissue. Based on this, it would be interesting to evaluate markers derived from the neural crest that may be useful in PC. Additionally, CD56, a membrane glycoprotein and a member of the immunoglobulin superfamily, has been described as a negative marker in PC, despite being commonly seen in neuroendocrine tumors of other organs. CD56 is not expressed in normal PT tissue or proliferative disorders, and its presence can help rule out a PT origin of the tumor [16,53].

3. Parathyroid Carcinoma Genomics

Advances in genomics are emerging and have enormous potential as they could be used relatively simply and reliably as diagnostic tools or decision aids.
Firstly, the CDC73 gene (also known as HRPT2) is a tumor suppressor gene that encodes a protein called parafibromin (whose function has been previously mentioned). Multiple somatic and germline mutations associated with partial or total inactivation of this gene have been identified. Somatic mutations in this gene are estimated to be the main genetic alteration in sporadic PC, present in two-thirds of cases (reports vary between 9-70%). Germline mutations are associated with HPT-JT syndrome, a population with a 20% probability of developing PC [54,55].
Secondly, the PRUNE2 gene encodes the homonymous protein, which has tumor suppressor activity by suppressing the activity of RhoA, inhibiting oncogenic transformation. Recently, Yu et al. detected several mutations via whole-exome sequencing in 18% of patients with PC, but did not describe this mutation in PT adenomas. This could represent PRUNE2 as a marker that differentiates between both conditions [55,56].
Furthermore, the CCND1 gene acts as an oncogene in PT adenomas through the PTH-CCND1 rearrangement. This gene encodes cyclin D1, whose amplification has been observed in up to 71-90% of PC and is associated with cell proliferation. Recent studies have shown that amplification of CCND1 can be mutually exclusive with somatic mutations in CDC73, suggesting alternative mechanisms of malignancy [52,55].
On the other hand, multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant endocrine disorder caused by mutations in the MEN1 gene. While this syndrome is commonly associated with PT adenomas or hyperplasia, around 1% of cases may present with PC. Recent studies indicate that mutations in this gene may be present in approximately 13 to 31% of cases of PC, so additional studies could position it as a marker of the disease [55].
Genes associated with the PI3K/AKT/mTOR and Wnt signaling pathways have also been implicated in PC. The first signaling pathway plays a physiological role in cell growth and survival, and its overactivation has been associated with various types of cancers, particularly through increased cell growth, angiogenesis, suppression of senescence and autophagy, as well as increased metastatic potential. Mutations in the PI3K/AKT/mTOR pathway have been described in 13-20% of PC cases, making it a potential target for inhibitors of this pathway [55,57].
Similarly, the Wnt signaling pathway is physiologically associated with cell proliferation, survival, and apoptosis. Aberrant activation of this pathway has also been implicated in multiple neoplasms. It has been described that CDC73 regulates this pathway through stabilization of beta-catenin. In addition, recent studies have identified a regulatory role of this pathway through genetic and epigenetic changes in APC and RNF43, observed in rare cases of PC as well as colorectal and endometrial carcinomas [55].
Finally, somatic mutations have been described in other genes such as TERT, which is associated with telomerase activity through the coding of its catalytic subunit. Additionally, mutations have been identified in genes AKAP9 (signal transduction pathway), FAT3 (cellular adhesion), and ZEB1 (EMT), the latter of which was mentioned previously [55].

4. Epigenetics: miRNAs, lncRNAs, circRNAs

Epigenetics plays a crucial role in tumorigenesis. It encompasses all intracellular mechanisms involved in the modulation of gene expression without altering the DNA sequence. Within this field, the action of non-coding RNAs (ncRNAs) at the post-transcriptional level is noteworthy. These ncRNAs can be classified based on length into small RNAs (sRNAs) or long non-coding RNAs (lncRNAs), with lengths less than or greater than 200 nucleotides, respectively. Specifically, the former group includes microRNAs (miRNAs), while the latter encompasses a circular group of lncRNAs called circRNAs. Similar to tissue biomarkers, ncRNAs have been used to differentiate adenomas from carcinomas, with variable results, and so far, no pathognomonic marker for the disease has been identified [58].
MiRNAs (or miRs) regulate gene expression at the post-transcriptional level, usually through negative regulation of mRNA, specifically by binding to complementary sites (typically in the UTR region). These miRNAs have different expression patterns in tissues and serum, with the latter location providing the theoretical basis for liquid biopsies, with potential applications in non-invasive diagnosis and monitoring. Specifically, in the context of the PT gland, miRNAs participate in the regulation of hormonal synthesis and secretion, as well as tumorigenesis [59].
At the serum level, Wang et al. described a significant up-regulation of MiR-27a-5p in serum exosomes of patients with PC; revealing an area under the curve (AUC) of 0.859. It is relevant that this specific miRNA participates in the activation of the Wnt/β-catenin signaling pathway, playing a key role in the process of EMT [60].
On the other hand, Krupinova et al. reported that miR-342-3p is significantly decreased in PC, with an AUC of 0.89 when used as a biomarker [59,61].
Studies evaluating miRNA expression at the tissue level have shown variable results. Corbetta et al. found that miR-296 (downregulated in PC), miR-222, and miR-503 (upregulated in PC) varied significantly between adenomas and PC. On the other hand, higher levels of HGS mRNA (hepatocyte growth factor receptor-regulated tyrosine kinase substrate) were observed in PC, which has been associated with EMT-related phenomena such as downregulation of E-Cadherin and subsequent increase in invasion and metastasis. Interestingly, HGS mRNA is a direct target of miR-296, and miR-296 undergoes significant downregulation during tumor progression. Consequently, an indirect role of miR-296 in the carcinogenesis of PT is suggested [62].
In parallel, Rahbari et al. reported significant variation of three miRNAs in PC: miR-26b, miR-30b, and miR-126. Notably, miR-126 showed better characteristics as a biomarker, with an AUC of 0.776 [63].
On the other hand, Vaira et al. described that aberrations in the expression of miRNAs from the C19MC cluster are a characteristic of PC compared to PT adenomas. This cluster of miRNAs is usually silenced by hypermethylation in adults, and its association with various human tumors has been described, promoting tumor invasion and metastasis. Specifically within this cluster, miR-517c showed the most notable difference, correlating with tumor weight, serum calcium, and PTH levels [64].
Additionally, increased expression of miRNAs from the C19MC cluster and miR-372 has been identified in PC distant metastases [59]. Finally, Hu et al. report that in a Chinese population (which has a higher incidence of PC, accounting for 5-7% of HPTP cases), the following miRNAs showed differential expression between PC and PT adenomas: miR-139, miR-222, miR-30b, miR-517c, and miR-126. Specifically, the combination of miR-139 and miR-30b was found to be the best biomarker with an AUC of 0.89 [59,65]. It is important to highlight that most of these studies are limited by small sample sizes due to the low frequency of this cancer.
On the other hand, lncRNAs and circRNAs primarily act as endogenous competitive RNAs (binding to miRNAs and inhibiting their function), while circRNAs can also be translated into functional micropeptides. There are limited studies on these ncRNAs in PC. In brief, Jiang et al. described that a profile composed of the lncRNAs: LINC00959, lnc-FLT3-2:2, lnc-FEZF2-9:2, and lnc-RP11-1035H13.3.1-2:1 had an AUC of 0.88, with Sen: 81.8% and Spe: 83.9% for differentiating adenomas from PC [66].
Furthermore, Zhang et al. recently described that alterations in the expression of lncRNAs PVT1 and GLIS2-AS1 had AUC values of 0.871 and 0.860, respectively [67]. On the other hand, Hu et al. determined that circRNA_0075005 had an AUC of 0.77 for the same function [58,65].

5. Proteomics

There are limited studies on proteomic-based biomarkers in PC. Ciregia et al. documented 33 differentially expressed proteins between PC and PT adenomas. Among these, UCH-L1 (or PGP9.5) is notably overexpressed. It is an enzyme that belongs to the deubiquitinase family and is associated with carcinogenesis pathways, cell growth, DNA repair, and apoptosis. Additionally, a significant increase in ANXA2 protein has been described; a marker of aggressiveness in multiple gastrointestinal cancers, which acts by calcium-mediated binding to membrane phospholipids. Other potential markers could be MDH1, CLIC1, and SOD2 [55,68].

6. Inflammatory Markers

In addition to the previously described markers, the use of preoperative inflammatory markers to distinguish PC from PT adenomas is noteworthy. For example, Ohkuwa et al. evaluated the neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and lymphocyte-monocyte ratio (LMR), and found that LMR is significantly decreased in PC and is an independent predictor of this cancer when <4.85 [69].

7. Use of Panels

Given that none of the mentioned markers are pathognomonic of parathyroid cancer, the creation of panels, nomograms or other systems that allow for the combination of different markers has become common. These instruments offer an increased sensitivity, specificity, positive predictive value, and negative predictive value therefore maximizing the diagnostic performance of these markers.
Briefly, we present some examples: Kumari et al. describe that a panel combination of parafibromin, galectin-3, and PGP9.5 presents a Sen: 50%, Spe: 97.9%, and a predictive accuracy of 95.4% [37] On the other hand, Truran et al. determined that the use of an immunohistochemical panel using the same markers described previously plus Ki67 is better than the isolated use of any single marker (Sen: 79% and Spe: 100%). These authors point out that a positivity greater than 5% of the cells to Ki57 is considered suspicious of being PC [70]. Finally, Silva-Figueroa et al. developed a nomogram using IHC biomarkers: parafibromin, Rb, Ki67, E-cadherin, and galectin-3, which showed an AUC of 84.9% (adjusted AUC for optimism: 80.5%) [71].

3. Conclusion

The progress made in the field of PC in recent years is evident; however, due to its low frequency it remains a poorly studied cancer. The identification of new diagnostic markers can aid in medical and surgical decision-making. Therefore, it is crucial to establish collaborative basic-clinical research projects that can identify new markers and therefore make a more efficient diagnostic process, as well as, help guide therapeutic and follow-up strategies.

4. Patents

This section is not mandatory but may be added if there are patents resulting from the work reported in this manuscript.

Author Contributions

Equal contribution by authors regarding: conceptualization, methodology, investigation, writing—original draft preparation, writing—review and editing. All authors have read and agreed to the published version of the manuscript.”.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

All supporting data of this manuscript are available upon request to corresponding authors.

Acknowledgments

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Bilezikian JP, Bandeira L, Khan A, Cusano NE. Hyperparathyroidism. Lancet. 2018 Jan 13;391(10116):168-178. Epub 2017 Sep 17. PMID: 28923463. [CrossRef]
  2. Walker MD, Silverberg SJ. Primary hyperparathyroidism. Nat Rev Endocrinol. 2018 Feb;14(2):115-125. Epub 2017 Sep 8. PMID: 28885621; PMCID: PMC6037987. [CrossRef]
  3. Erickson LA, Mete O, Juhlin CC, Perren A, Gill AJ. Overview of the 2022 WHO Classification of Parathyroid Tumors. Endocr Pathol. 2022 Mar;33(1):64-89. Epub 2022 Feb 17. PMID: 35175514. [CrossRef]
  4. Minisola S, Arnold A, Belaya Z, Brandi ML, Clarke BL, Hannan FM, Hofbauer LC, Insogna KL, Lacroix A, Liberman U, Palermo A, Pepe J, Rizzoli R, Wermers R, Thakker RV. Epidemiology, Pathophysiology, and Genetics of Primary Hyperparathyroidism. J Bone Miner Res. 2022 Nov;37(11):2315-2329. Epub 2022 Oct 17. PMID: 36245271. [CrossRef]
  5. Yeh MW, Ituarte PH, Zhou HC, et al. Incidence and prevalence of pri-mary hyperparathyroidism in a racially mixed population. J ClinEndocrinol Metab. 2013;98(3):1122-1129.
  6. Guilmette J, Sadow PM. Parathyroid Pathology. Surg Pathol Clin. 2019 Dec;12(4):1007-1019. Epub 2019 Sep 27. PMID: 31672291; PMCID: PMC7395581. [CrossRef]
  7. Rappoport W., Daniel, Caballero Q., María Gabriela, Cortés B., Natalia, Cabané T., Patricio, Gac E., Patricio, & Rodríguez M., Francisco. (2021). Hiperparatiroidismo primario. Revista de cirugía, 73(2), 222-226. https://dx.doi.org/10.35687/s2452-45492021002910.
  8. Bilezikian JP, Khan AA, Silverberg SJ, Fuleihan GE, Marcocci C, Minisola S, Perrier N, Sitges-Serra A, Thakker RV, Guyatt G, Mannstadt M, Potts JT, Clarke BL, Brandi ML; International Workshop on Primary Hyperparathyroidism. Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop. J Bone Miner Res. 2022 Nov;37(11):2293-2314. Epub 2022 Oct 17. PMID: 36245251. [CrossRef]
  9. Insogna KL. Primary Hyperparathyroidism. N Engl J Med. 2018 Sep 13;379(11):1050-1059. PMID: 30207907. [CrossRef]
  10. Cetani F, Pardi E, Marcocci C. Parathyroid Carcinoma. Front Horm Res. 2019;51:63-76. Epub 2018 Nov 19. PMID: 30641523. [CrossRef]
  11. Ullah A, Khan J, Waheed A, Sharma N, Pryor EK, Stumpe TR, Velasquez Zarate L, Cason FD, Kumar S, Misra S, Kavuri S, Mesa H, Roper N, Foroutan S, Karki NR, Del Rivero J, Simonds WF, Karim NA. Parathyroid Carcinoma: Incidence, Survival Analysis, and Management: A Study from the SEER Database and Insights into Future Therapeutic Perspectives. Cancers (Basel). 2022 Mar 10;14(6):1426. PMID: 35326576; PMCID: PMC8946517. [CrossRef]
  12. Salcuni AS, Cetani F, Guarnieri V, Nicastro V, Romagnoli E, de Martino D, Scillitani A, Cole DEC. Parathyroid carcinoma. Best Pract Res Clin Endocrinol Metab. 2018 Dec;32(6):877-889. Epub 2018 Dec 1. PMID: 30551989.https://doi.org/10.1016/j.beem.2018.11.002.
  13. Zheng H-c, Xue H and Zhang C-y (2022), The roles of the tumor suppressor parafibromin in cancer. Front. Cell Dev. Biol. 10:1006400. [CrossRef]
  14. Barberán Marcela, Campusano Claudia, Salman Patricio, Trejo Pamela, Silva-Figueroa Angélica, Rivera Sandra et al. . Puesta al día: carcinoma paratiroideo. Rev. méd. Chile [Internet]. 2021 Mar [citado 2023 Ene 24] ; 149( 3 ): 399-408. Disponible en: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872021000300399&lng=es. [CrossRef]
  15. Cabané T Patricio, Carredano C Miren, Rappoport W Daniel, Pineda B Pedro, Carreño T Laura, Passalaqua R Walter et al. . Paratirotoxicosis y tumor cervical palpable: caso clínico de cáncer de paratiroides. Rev Chil Cir [Internet]. 2017 Jun [citado 2023 Ene 24] ; 69( 3 ): 247-251. Disponible en: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0718-40262017000300012&lng=es. [CrossRef]
  16. Uljanovs R, Sinkarevs S, Strumfs B, Vidusa L, Merkurjeva K, Strumfa I. Immunohistochemical Profile of Parathyroid Tumours: A Comprehensive Review. Int J Mol Sci. 2022 Jun 23;23(13):6981. PMID: 35805976; PMCID: PMC9266566. [CrossRef]
  17. Christakis I, Silva AM, Kwatampora LJ, Warneke CL, Clarke CN, Williams MD, Grubbs EG, Lee JE, Busaidy NL, Perrier ND. Oncologic progress for the treatment of parathyroid carcinoma is needed. J Surg Oncol. 2016 Nov;114(6):708-713. Epub 2016 Oct 18. PMID: 27753088. [CrossRef]
  18. Mohebati A, Shaha A, Shah J. Parathyroid carcinoma: challenges in diagnosis and treatment. Hematol Oncol Clin North Am. 2012 Dec;26(6):1221-38. Epub 2012 Oct 5. PMID: 23116578. [CrossRef]
  19. Rozhinskaya L, Pigarova E, Sabanova E, Mamedova E, Voronkova I, Krupinova J, Dzeranova L, Tiulpakov A, Gorbunova V, Orel N, Zalian A, Melnichenko G, Dedov I. Diagnosis and treatment challenges of parathyroid carcinoma in a 27-year-old woman with multiple lung metastases. Endocrinol Diabetes Metab Case Rep. 2017 Mar 13;2017:16-0113. PMID: 28458892; PMCID: PMC5404464. [CrossRef]
  20. Davies, M. P., John Evans, T. W., Tahir, F., & Balasubramanian, S. P. (2021). Parathyroid cancer: A systematic review of diagnostic biomarkers. The Surgeon. [CrossRef]
  21. Juhlin CC, Nilsson IL, Lagerstedt-Robinson K, Stenman A, Bränström R, Tham E, Höög A. Parafibromin immunostainings of parathyroid tumors in clinical routine: a near-decade experience from a tertiary center. Mod Pathol. 2019.
  22. Farhad M, Rolig AS, Redmond WL. The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment. Oncoimmunology. 2018 Feb 20;7(6):e1434467. PMID: 29872573; PMCID: PMC5980349.https://doi.org/10.1080/2162402X.2018.1434467.
  23. Hosny Mohammed K, Siddiqui MT, Willis BC, Zaharieva Tsvetkova D, Mohamed A, Patel S, Sharma J, Weber C, Cohen C. Parafibromin, APC, and MIB-1 Are Useful Markers for Distinguishing Parathyroid Carcinomas From Adenomas. Appl Immunohistochem Mol Morphol. 2017 Nov/Dec;25(10):731-735. PMID: 27490759. [CrossRef]
  24. La Rosa S. Diagnostic, Prognostic, and Predictive Role of Ki67 Proliferative Index in Neuroendocrine and Endocrine Neoplasms: Past, Present, and Future. Endocr Pathol. 2023 Mar;34(1):79-97. Epub 2023 Feb 17. PMID: 36797453; PMCID: PMC10011307. [CrossRef]
  25. Truran PP, Johnson SJ, Bliss RD, Lennard TW, Aspinall SR. Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer. World J Surg. 2014 Nov;38(11):2845-54. PMID: 25002250. [CrossRef]
  26. Storvall S, Leijon H, Ryhänen EM, Vesterinen T, Heiskanen I, Schalin-Jäntti C, Arola J. Filamin A and parafibromin expression in parathyroid carcinoma. Eur J Endocrinol. 2021 Oct 25;185(6):803-812. PMID: 34606470https://doi.org/10.1530/EJE-21-0668.
  27. Xue S, Chen H, Lv C, Shen X, Ding J, Liu J, Chen X. Preoperative diagnosis and prognosis in 40 Parathyroid Carcinoma Patients. Clin Endocrinol (Oxf). 2016 Jul;85(1):29-36. Epub 2016 Mar 31. PMID: 26939543. [CrossRef]
  28. Hu Y, Zhang X, Cui M, Su Z, Wang M, Liao Q, Zhao Y. Verification of candidate microRNA markers for parathyroid carcinoma. Endocrine. 2018 May;60(2):246-254. Epub 2018 Feb 16. PMID: 29453660. [CrossRef]
  29. Christakis I, Bussaidy N, Clarke C, Kwatampora LJ, Warneke CL, Silva AM, Williams MD, Grubbs EG, Lee JE, Perrier ND. Differentiating Atypical Parathyroid Neoplasm from Parathyroid Cancer. Ann Surg Oncol. 2016 Sep;23(9):2889-97. Epub 2016 May 9. PMID: 27160525. [CrossRef]
  30. Quinn CE, Healy J, Lebastchi AH, Brown TC, Stein JE, Prasad ML, Callender GG, Carling T, Udelsman R. Modern experience with aggressive parathyroid tumors in a high-volume New England referral center. J Am Coll Surg. 2015 Jun;220(6):1054-62. Epub 2014 Oct 24. PMID: 25488353. [CrossRef]
  31. Favia G, Lumachi F, Polistina F, D’Amico DF. Parathyroid carcinoma: sixteen new cases and suggestions for correct management. World J Surg. 1998 Dec;22(12):1225-30. PMID: 9841748. [CrossRef]
  32. Bae JH, Choi HJ, Lee Y, Moon MK, Park YJ, Shin CS, Park DJ, Jang HC, Kim SY, Kim SW. Preoperative predictive factors for parathyroid carcinoma in patients with primary hyperparathyroidism. J Korean Med Sci. 2012 Aug;27(8):890-5. Epub 2012 Jul 25. PMID: 22876055; PMCID: PMC3410236. [CrossRef]
  33. Ryhänen EM, Leijon H, Metso S, Eloranta E, Korsoff P, Ahtiainen P, Kekäläinen P, Tamminen M, Ristamäki R, Knutar O, Löyttyniemi E, Niskanen L, Väisänen M, Heiskanen I, Välimäki MJ, Laakso M, Haglund C, Arola J, Schalin-Jäntti C. A nationwide study on parathyroid carcinoma. Acta Oncol. 2017 Jul;56(7):991-1003. Epub 2017 Mar 31. PMID: 28362521. [CrossRef]
  34. Guarnieri V, Battista C, Muscarella LA, Bisceglia M, de Martino D, Baorda F, Maiello E, D’Agruma L, Chiodini I, Clemente C, Minisola S, Romagnoli E, Corbetta S, Viti R, Eller-Vainicher C, Spada A, Iacobellis M, Malavolta N, Carella M, Canaff L, Hendy GN, Cole DE, Scillitani A. CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort. Cell Oncol (Dordr). 2012 Dec;35(6):411-22. Epub 2012 Sep 18. PMID: 22987117. [CrossRef]
  35. Niramitmahapanya S, Sunthornthepvarakul T, Deerochanawong C, Sarinnapakorn V, Athipan P, Harnsomboonvana P, Kongsaengdao S. Sensitivity of HRPT2 mutation screening to detect parathyroid carcinoma and atypical parathyroid adenoma of Thai patients. J Med Assoc Thai. 2011 Mar;94 Suppl 2:S17-22. PMID: 21717873.
  36. Cetani F, Ambrogini E, Viacava P, Pardi E, Fanelli G, Naccarato AG, Borsari S, Lemmi M, Berti P, Miccoli P, Pinchera A, Marcocci C. Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur J Endocrinol. 2007 May;156(5):547-54. PMID: 17468190. [CrossRef]
  37. Kumari N, Chaudhary N, Pradhan R, Agarwal A, Krishnani N. Role of Histological Criteria and Immunohistochemical Markers in Predicting Risk of Malignancy in Parathyroid Neoplasms. Endocr Pathol. 2016 Jun;27(2):87-96. PMID: 26984237. [CrossRef]
  38. Wang O, Wang CY, Shi J, Nie M, Xia WB, Li M, Jiang Y, Guan H, Meng XW, Xing XP. Expression of Ki-67, galectin-3, fragile histidine triad, and parafibromin in malignant and benign parathyroid tumors. Chin Med J (Engl). 2012 Aug;125(16):2895-901. PMID: 22932087.
  39. Saggiorato E, Bergero N, Volante M, Bacillo E, Rosas R, Gasparri G, Orlandi F, Papotti M. Galectin-3 and Ki-67 expression in multiglandular parathyroid lesions. Am J Clin Pathol. 2006 Jul;126(1):59-66. PMID: 16753595. [CrossRef]
  40. Sungu N, Dogan HT, Kiliçarslan A, Kiliç M, Polat S, Tokaç M, Akbaba S, Parlak Ö, Balci S, Ögüt B, Çakir B. Role of calcium-sensing receptor, Galectin-3, Cyclin D1, and Ki-67 immunohistochemistry to favor in the diagnosis of parathyroid carcinoma. Indian J Pathol Microbiol. 2018 Jan-Mar;61(1):22-26. PMID: 29567879. [CrossRef]
  41. Howell VM, Gill A, Clarkson A, Nelson AE, Dunne R, Delbridge LW, Robinson BG, Teh BT, Gimm O, Marsh DJ. Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. J Clin Endocrinol Metab. 2009 Feb;94(2):434-41. Epub 2008 Nov 18. PMID: 19017757. [CrossRef]
  42. Juhlin CC, Haglund F, Villablanca A, Forsberg L, Sandelin K, Bränström R, Larsson C, Höög A. Loss of expression for the Wnt pathway components adenomatous polyposis coli and glycogen synthase kinase 3-beta in parathyroid carcinomas. Int J Oncol. 2009 Feb;34(2):481-92. PMID: 19148484.
  43. Fernandez-Ranvier GG, Khanafshar E, Tacha D, Wong M, Kebebew E, Duh QY, Clark OH. Defining a molecular phenotype for benign and malignant parathyroid tumors. Cancer. 2009 Jan 15;115(2):334-44. PMID: 19107770. [CrossRef]
  44. Bergero N, De Pompa R, Sacerdote C, Gasparri G, Volante M, Bussolati G, Papotti M. Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases. Hum Pathol. 2005 Aug;36(8):908-14. PMID: 16112008. [CrossRef]
  45. Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M, et al. Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol [Internet]. 2020;21(6):341–52. Disponible en. [CrossRef]
  46. Baldini E, Tuccilli C, Pironi D, Catania A, Tartaglia F, Di Matteo FM, et al. Expression and clinical utility of transcription factors involved in epithelial-mesenchymal transition during thyroid cancer progression. J Clin Med [Internet]. 2021;10(18):4076. Disponible en:. [CrossRef]
  47. Ribatti D, Tamma R, Annese T. Epithelial-mesenchymal transition in cancer: A historical overview. Transl Oncol [Internet]. 2020;13(6):100773. Disponible en:. [CrossRef]
  48. Atashzar MR, Baharlou R, Karami J, Abdollahi H, Rezaei R, Pourramezan F, et al. Cancer stem cells: A review from origin to therapeutic implications. J Cell Physiol [Internet]. 2020;235(2):790–803. Disponible en. [CrossRef]
  49. Walcher L, Kistenmacher A-K, Suo H, Kitte R, Dluczek S, Strauß A, et al. Cancer stem cells-origins and biomarkers: Perspectives for targeted personalized therapies. Front Immunol [Internet]. 2020;11:1280. Disponible en:. [CrossRef]
  50. Fendrich V, Waldmann J, Feldmann G, Schlosser K, König A, Ramaswamy A, Bartsch DK, Karakas E. Unique expression pattern of the EMT markers Snail, Twist and E-cadherin in benign and malignant parathyroid neoplasia. Eur J Endocrinol. 2009 Apr;160(4):695-703. Epub 2009 Jan 28. PMID: 19176646. [CrossRef]
  51. Schneider R, Bartsch-Herzog S, Ramaswamy A, Bartsch DK, Karakas E. Immunohistochemical Expression of E-Cadherin in Atypical Parathyroid Adenoma. World J Surg. 2015 Oct;39(10):2477-83. PMID: 26154578. [CrossRef]
  52. Pandya C, Uzilov AV, Bellizzi J, Lau CY, Moe AS, Strahl M, Hamou W, Newman LC, Fink MY, Antipin Y, Yu W, Stevenson M, Cavaco BM, Teh BT, Thakker RV, Morreau H, Schadt EE, Sebra R, Li SD, Arnold A, Chen R. Genomic profiling reveals mutational landscape in parathyroid carcinomas. JCI Insight. 2017 Mar 23;2(6):e92061. PMID: 28352668; PMCID: PMC535848. [CrossRef]
  53. Uljanovs R, Strumfa I, Bahs G, Vidusa L, Merkurjeva K, Franckevica I, Strumfs B. Molecular profile of parathyroid tissues and tumours: a heterogeneous landscape. Pol J Pathol. 2021;72(2):99-116. PMID: 34706517. [CrossRef]
  54. Li, Y., Zhang, J., Adikaram, P. R., Welch, J., Guan, B., Weinstein, L. S., Chen, H., & Simonds, W. F. (2020). Genotype of CDC73 germline mutation determines risk of parathyroid cancer, Endocrine-Related Cancer, 27(9), 483-494. Retrieved Feb 8, 2023, from https://erc.bioscientifica.com/view/journals/erc/27/9/ERC-20-0149.xml.
  55. Kong, S.H. Updates of Genomics and Proteomics of Parathyroid Carcinoma. Endocrines 2022, 3, 745–752. [CrossRef]
  56. Yu W, McPherson JR, Stevenson M, van Eijk R, Heng HL, Newey P, Gan A, Ruano D, Huang D, Poon SL, Ong CK, van Wezel T, Cavaco B, Rozen SG, Tan P, Teh BT, Thakker RV, Morreau H. Whole-exome sequencing studies of parathyroid carcinomas reveal novel PRUNE2 mutations, distinctive mutational spectra related to APOBEC-catalyzed DNA mutagenesis and mutational enrichment in kinases associated with cell migration and invasion. J Clin Endocrinol Metab. 2015 Feb;100(2):E360-4. Epub 2014 Nov 11. PMID: 25387265. [CrossRef]
  57. Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR Signaling in Cancer. Front Oncol. 2014 Apr 14;4:64. PMID: 24782981; PMCID: PMC3995050. [CrossRef]
  58. Kong, S.H. Updates of Genomics and Proteomics of Parathyroid Carcinoma. Endocrines 2022, 3, 745–752. [CrossRef]
  59. Aurilia, C.; Donati, S.; Palmini, G.; Miglietta, F.; Falsetti, I.; Iantomasi, T.; Brandi, M.L. Are Non-Coding RNAs Useful Biomarkers in Parathyroid Tumorigenesis? Int. J. Mol. Sci. 2021, 22, 10465. [CrossRef]
  60. Wielogórska, M.; Podgórska, B.; Niemira, M.; Szelachowska, M.; Kr ̨etowski, A.; Siewko, K. MicroRNA Profile Alterations in Parathyroid Carcinoma: Latest Updates and Perspectives. Cancers 2022, 14, 876. [CrossRef]
  61. Wang J, Wang Q, Zhao T, Liu X, Bai G, Xin Y, Shen H, Wei B. Expression profile of serum-related exosomal miRNAs from parathyroid tumor. Endocrine. 2021 Apr;72(1):239-248. Epub 2020 Nov 8. PMID: 33161496. [CrossRef]
  62. Krupinova J, Mokrysheva N, Petrov V, Pigarova E, Eremkina A, Dobreva E, Ajnetdinova A, Melnichenko G, Tiulpakov A. Serum circulating miRNA-342-3p as a potential diagnostic biomarker in parathyroid carcinomas: A pilot study. Endocrinol Diabetes Metab. 2021 Oct;4(4):e00284. Epub 2021 Jul 29. PMID: 34505413; PMCID: PMC8502227. [CrossRef]
  63. Corbetta, S., Vaira, V., Guarnieri, V., Scillitani, A., Eller-Vainicher, C., Ferrero, S., Vicentini, L., Chiodini, I., Bisceglia, M., Beck-Peccoz, P., Bosari, S., & Spada, A. (2010). Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue, Endocrine-Related Cancer, 17(1), 135-146. Retrieved Feb 23, 2023, from https://erc.bioscientifica.com/view/journals/erc/17/1/135.xml.
  64. Rahbari, R., Holloway, A.K., He, M. et al. Identification of Differentially Expressed MicroRNA in Parathyroid Tumors. Ann Surg Oncol 18, 1158–1165 (2011). [CrossRef]
  65. Vaira, V., Elli, F., Forno, I., Guarnieri, V., Verdelli, C., Ferrero, S., Scillitani, A., Vicentini, L., Cetani, F., Mantovani, G., Spada, A., Bosari, S., & Corbetta, S. (2012). The microRNA cluster C19MC is deregulated in parathyroid tumours, Journal of Molecular Endocrinology, 49(2), 115-124. Retrieved Feb 23, 2023, from https://jme.bioscientifica.com/view/journals/jme/49/2/115.xml.
  66. Hu Y, Zhang X, Cui M, Wang M, Su Z, Liao Q, Zhao Y. Circular RNA profile of parathyroid neoplasms: analysis of co-expression networks of circular RNAs and mRNAs. RNA Biol. 2019 Sep;16(9):1228-1236. Epub 2019 Jun 18. PMID: 31213128; PMCID: PMC6693544. [CrossRef]
  67. Jiang, T., Wei, B.J., Zhang, D.X. et al. Genome-wide analysis of differentially expressed lncRNA in sporadic parathyroid tumors. Osteoporos Int 30, 1511–1519 (2019). [CrossRef]
  68. Zhang X, Hu Y, Wang M, Zhang R, Wang P, Cui M, Su Z, Gao X, Liao Q, Zhao Y. Profiling analysis of long non-coding RNA and mRNA in parathyroid carcinoma. Endocr Relat Cancer. 2019 Feb;26(2):163-176. PMID: 30403657. [CrossRef]
  69. Ciregia F, Cetani F, Pardi E, Soggiu A, Piras C, Zallocco L, Borsari S, Ronci M, Caruso V, Marcocci C, Mazzoni MR, Lucacchini A, Giusti L. Parathyroid Carcinoma and Adenoma Co-existing in One Patient: Case Report and Comparative Proteomic Analysis. Cancer Genomics Proteomics. 2021 Nov-Dec;18(6):781-796. PMID: 34697069; PMCID: PMC8569818. [CrossRef]
  70. Ohkuwa K, Sugino K, Katoh R, Nagahama M, Kitagawa W, Matsuzu K, Suzuki A, Tomoda C, Hames K, Akaishi J, Masaki C, Yoshioka K, Ito K. Preoperative inflammatory markers for predicting parathyroid carcinoma. Endocr Connect. 2022 Jul 14;11(7):e220062. PMID: 35700222; PMCID: PMC9346317. [CrossRef]
  71. Truran PP, Johnson SJ, Bliss RD, Lennard TW, Aspinall SR. Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer. World J Surg. 2014 Nov;38(11):2845-54. PMID: 25002250. [CrossRef]
  72. Silva-Figueroa, A.M., Bassett, R., Christakis, I. et al. Using a Novel Diagnostic Nomogram to Differentiate Malignant from Benign Parathyroid Neoplasms. Endocr Pathol 30, 285–296 (2019). [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated